About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Myxedema of Upper Airway: A Rare Cause of Stridor

viagra pro mlade

viagra

morphine with naltrexone and naloxone

naloxone or naltrexone go
Vijay Bidkar, Ashok Naik, Roshan J, Anita BS1
From the Department of ENT & Head Neck Surgery and Department of Pathology1, SDM College of Medical Sciences & Hospital, Dharwad, Karnataka, India.
Corresponding Author:
Dr.Vijay Bidkar
Email: vijay20dr@gmail.com
Received: 11 JULY 2013 Accepted: 22-JULY-2013 Published Online: 05-AUG-2013
DOI: http://dx.doi.org/10.17659/01.2013.0059
Abstract
Hypothyroidism is known to affect breathing by reducing respiratory drive. Near total narrowing of naso- oropharynx and larynx due to myxedema of upper airway in an undiagnosed severe hypothyroidism is a rare phenomenon. We report a case of non goitorous severe hypothyroidism presenting with upper airway obstruction in a 60 year old male- a diagnostic challenge in acute onset airway obstruction. An upper airway myxedema and hypertrophic myopathy of pharyngeal dilator muscles in hypothyroidism can present with severe acute airway compromise in absence of goitorous enlargement of the thyroid gland.
Keywords : Airway Obstruction, Hypothyroidism, Myxedema, Muscle Diseases, Oropharynx.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 02, 2025